Docoh
Loading...

TARO Taro Pharmaceutical Industries

APP
Utility
Topical Montelukast Formulations
23 Dec 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
Filed: 2 Aug 21
GRANT
Utility
Topical Montelukast formulations
16 Nov 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Vered Rosenberger, Helena Shifrin, Irena Oleinik, Tzviel Sheskin, Ron Schlinger, Avi Avramoff
Filed: 2 Feb 21
APP
Utility
Topical Montelukast Formulations
5 Aug 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
Filed: 2 Feb 21
APP
Utility
Topical Capecitabine for the Treatment of Hyperproliferative Skin Conditions
25 Feb 21
The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition.
Avi AVRAMOFF, Helena SHIFRIN, Ron SCHLINGER, Tzviel SHESKIN, Zeev ELKOSHI
Filed: 18 Jan 19
APP
Utility
Topical Montelukast for Treatment of Atopic Dermatitis
29 Jul 20
A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.
Avi AVRAMOFF, Helena SHIFRIN, Irena OLEINIK, Ron SCHLINGER, Tzviel SHESKIN, Vered ROSENBERGER
Filed: 8 Jan 20
GRANT
Utility
Topical montelukast for treatment of atopic dermatitis
3 Feb 20
A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.
Avi Avramoff, Helena Shifrin, Irena Oleinik, Ron Schlinger, Tzviel Sheskin, Vered Rosenberger
Filed: 2 May 17
APP
Utility
Fenoldopam Topical Formulations for Treating Skin Disorders
30 Oct 19
Wahid KHAN, Helena SHIFRIN, Ron SCHLINGER, Avi AVRAMOFF, Avi DOMB
Filed: 29 Aug 17
  • 1
Patents are sorted by USPTO publication date, most recent first